Welcome to our dedicated page for NuCana plc SEC filings (Ticker: NCNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NuCana plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NuCana plc's regulatory disclosures and financial reporting.
NuCana plc Chief Medical Officer Jeffrey D. Bloss filed a Form 3 reporting his existing ownership in the company. The filing lists multiple option awards over Ordinary Shares with exercise prices between 0.0004 and 0.004 Pounds Sterling, including grants that are fully vested and others that vest between June 2026 and January 2027, subject to continued service. Bloss also reports direct ownership of 47,136 Ordinary Shares.
NuCana plc reports its 2025 annual results and outlines key risks around its oncology pipeline and funding. The company recorded net losses of £19.0 million in 2024 and £29.4 million in 2025, bringing its accumulated deficit to £252.3 million as of December 31, 2025.
Cash and cash equivalents were £24.3 million at year-end, which management believes will fund operations for at least twelve months, though substantial additional financing will be needed longer term and going-concern risk is highlighted. NuCana’s lead candidates are NUC‑7738, in a Phase 1/2 trial for advanced solid tumors and PD‑1 inhibitor‑resistant melanoma, and NUC‑3373, recently evaluated in a Phase 1b/2 trial in combination regimens. The report emphasizes extensive development, regulatory, funding, market, operational and macroeconomic risks, and notes 20,809,854,947 ordinary shares outstanding as of December 31, 2025.
NuCana plc reported fourth quarter and full-year 2025 results and updated progress on its oncology pipeline. The company recorded a net loss of £2.5 million for Q4 2025 and £29.4 million for the year.
Cash and cash equivalents were £24.3 million as of December 31, 2025, helped by a May 2025 financing that raised £9.6 million in gross proceeds and a July 2025 at-the-market raise of £19.0 million. Management expects existing cash resources to fund planned operations into 2029.
Lead candidate NUC-7738 showed clinical activity and a favorable safety profile in PD‑1 inhibitor‑resistant metastatic melanoma, with partial responses and durable stable disease reported. NuCana plans to complete enrollment in the Phase 2 NuTide:701 expansion study in the first half of 2026 and seek FDA guidance on a potential registrational pathway.
NuCana plc Chief Executive Officer Hugh S. Griffith filed a Schedule 13D reporting beneficial ownership of 2,829,961,890 ordinary shares, equal to 12.0% of NuCana’s 20,809,854,947 ordinary shares outstanding as of March 18, 2026.
The holding includes 1,000,000 ordinary shares, 265,026 ordinary shares in the form of ADSs, and vested options to purchase 2,828,696,864 ordinary shares granted under the company’s equity plans. Griffith states the securities were acquired for investment, with no current plans for corporate actions described in Item 4, though he may change his intentions.
The filing notes it was submitted after the Section 13(d) deadline, attributing the delay to inadvertent administrative oversight and Griffith’s surgery and treatment for serious illness, and states he did not seek or believe he obtained any advantage from the late submission.
NuCana plc filed an initial statement of beneficial ownership for officer Ian Alexander Webster, outlining multiple option grants over its Ordinary Shares. These options carry exercise prices of 0.004 Pounds Sterling or 0.0004 Pounds Sterling, with varying vesting and expiration schedules.
Some option grants over Ordinary Shares completed vesting on June 20, 2025 and January 14, 2026, and expire on June 20, 2035 and January 14, 2036, respectively. Other grants begin vesting 25% on June 20, 2026 and January 14, 2027, with the remainder vesting in three equal annual installments, subject to continued service. The filing reports holdings only, with no buy or sell transactions.
NuCana plc director Kay Andrew Martin has filed an initial Form 3 disclosing significant option holdings over the company’s ordinary shares. The filing reports multiple option awards that together are exercisable into up to 63,648,062 and 52,934,010 Ordinary Shares at very low exercise prices.
According to the footnotes, some options have exercise prices between 0.0004 and 0.004 Pounds Sterling per Ordinary Share, with portions that completed vesting on June 20, 2025 and January 14, 2026 and expirations on June 20, 2035 and January 14, 2036. Other grants will vest in full on June 20, 2026 and January 14, 2027, subject to Martin’s continued service with NuCana through those vesting dates.
NuCana plc director Cyrille Leperlier reports existing stock option holdings over the company’s ordinary shares. The options are structured in four grants, each referencing ordinary shares with very low exercise prices between 0.0004 and 0.004 Pounds Sterling per share.
According to the terms, some grants are already fully vested and expire on June 20, 2035 and January 14, 2036. Other grants will vest in full on June 20, 2026 and January 14, 2027, provided Leperlier continues to serve with NuCana through those vesting dates.
NuCana plc Chief Operating Officer Theresa Margaret Bruce reported existing holdings of stock options over the company’s Ordinary Shares. One option grant over Ordinary Shares has an exercise price of 0.004 Pounds Sterling, fully vested on June 20, 2025, and expires on June 20, 2035. A second option grant over Ordinary Shares has an exercise price of 0.0004 Pounds Sterling and will vest 25% on June 20, 2026, with the remaining portions vesting in three equal annual installments, subject to her continued service with the company.
NuCana plc director and CEO Hugh Griffith has filed an initial Form 3 reporting his equity holdings in the company. He reports direct ownership of 1,000,000 Ordinary Shares and American Depositary Shares, with one entry showing 52 American Depositary Shares. According to the disclosure, each American Depositary Share represents 5,000 Ordinary Shares of NuCana plc.
The filing also lists several option awards over Ordinary Shares, all held directly. These include separate option positions over 62,499,995, 1,221,867,885, 1,544,328,984, 691,582,704 and 831,561,761 underlying Ordinary Shares, each with very low exercise prices in Pounds Sterling. Footnotes state that some options are fully vested and expire between June 20, 2035 and January 14, 2036, while others vest in annual installments through June 20, 2029 and January 14, 2030, subject to continued service.
NuCana plc reports that Hugh S. Griffith has returned to his role as Chief Executive Officer and principal executive officer, effective December 15, 2025.
During his health-related leave, Executive Chairman Andrew Kay had been acting as the company’s principal executive officer; upon Mr. Griffith’s return, Mr. Kay resumed his prior position as Chairman of the Board. The update is also stated to be incorporated by reference into NuCana’s existing shelf and equity compensation registration statements on Form F-3 and Form S-8.